Amundi
KRTX

Amundi’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Amundi’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14
Closed -$2.39K – 2099
2023
Q3 		$2.39K Hold
14
– – ﹤0.01% 1995
2023
Q2 		$3.05K Hold
14
– – ﹤0.01% 2012
2023
Q1 		$2.47K Hold
14
– – ﹤0.01% 2037
2022
Q4 		$2.74K Sell
14
-1,589
-99% -$341K ﹤0.01% 1871
2022
Q3 		$351K Hold
1,603
– – ﹤0.01% 1387
2022
Q2 		$211K Buy
1,603
+379
+31% +$43.6K ﹤0.01% 1356
2022
Q1 		$167K Hold
1,224
– – ﹤0.01% 1403
2021
Q4 		$150K Sell
1,224
-289
-19% -$37.4K ﹤0.01% 1515
2021
Q3 		$185K Hold
1,513
– – ﹤0.01% 1450
2021
Q2 		$172K Buy
+1,513
New +$177K ﹤0.01% 1410

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Amundi's KRTX Position: Q4 2023 in Review

Amundi sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 14 shares — an estimated $2.39K sold.

Amundi first reported a position in KRTX in Q2 2021 and held it in 10 quarters. The position peaked at $351K in Q3 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • Amundi reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Amundi sold 14 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.39K.
  • Amundi first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Amundi's Karuna Therapeutics, Inc. Common Stock position peaked at $351K in Q3 2022.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.